Key result
TLR4 signaling drives cardiomyocyte ferroptosis, emerging as a potential therapeutic target in heart failure.
Why the study?
Cardiomyocyte ferroptosis is a potential contributor to heart failure progression, but the regulatory mechanisms involving TLR4 signaling remain incompletely understood.
This review highlights the emerging role of TLR4 signaling in regulating cardiomyocyte ferroptosis, presenting it as a potential therapeutic target for heart failure management.
Iron is an essential nutrient for living organisms, and the maintenance of its homeostatic balance within the body is a critical factor in ensuring normal physiological functions. Cardiomyocyte ferroptosis has emerged as a potential contributor to heart failure progression, involving complex regulatory mechanisms that remain incompletely understood. While the TLR4 signaling pathway was traditionally regarded as a therapeutic target for chronic inflammatory conditions, emerging evidence indicates that its activation may contribute to ferroptosis in cardiomyocytes. The proposed mechanisms through which TLR4 signaling may regulate cardiomyocyte ferroptosis are systematically summarized, and several therapeutic strategies targeting TLR4-associated ferroptosis are evaluated. Furthermore, promising avenues for future investigation are discussed, with particular emphasis on the need for direct mechanistic validation in cardiomyocytes and in vivo models, which may ultimately inform novel therapeutic strategies for heart failure.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a review in Heart failure. TLR4-associated ferroptosis targeted therapies was evaluated. Activation of the TLR4 signaling pathway may contribute to ferroptosis in cardiomyocytes, representing a potential novel therapeutic target for the prevention and treatment of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: